Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | LPL | P06858 | 4/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31583865 | 1.00 | CSF1R (0.45) | CSF1RCA1CA2CA9LPL | |
| SCHEMBL9401 | 0.87 | MAOB (0.47) | CSF1RCA1CA2CA9LPL | |
| SCHEMBL25203373 | 0.84 | CSF1R (0.48) | CSF1RCA1CA2CA9LPL | |
| SCHEMBL1877988 | 0.84 | CSF1R (0.48) | CSF1RCA1CA2CA9LPL | |
| SCHEMBL796915 | 0.81 | CSF1R (0.49) | CSF1RCA1CA2CA9LPL | |
| SCHEMBL1129150 | 0.80 | TTR (0.48) | CA1CA2CA9LPLLIPG | |
| SCHEMBL5327244 | 0.80 | ALDH1A1 (0.46) | CSF1RCA1CA2CA9LPL | |
| SCHEMBL142144 | 0.80 | LPL (0.49) | CSF1RCA1CA2CA9LPL | |
| SCHEMBL16382812 | 0.80 | LIPG (0.44) | CSF1RCA1CA2CA9LPL | |
| SCHEMBL12006791 | 0.80 | CSF1R (0.43) | CSF1RCA1CA2CA9LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103275112-A | Method for continuously synthesizing arylboronic acid ester by utilizing microreactor | JINAN SHAOYUAN MEDICAL TECHNOLOGY CO LTD | 2013-09-04 | — | — | CN | claimed |
| EP-1127060-B8 | HYDROBORONATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2005-01-05 | — | — | EP | claimed |
| US-20040133028-A1 | Hydroboronation process | COMMONWEALTH SCIENTIFIC | 2004-07-08 | — | — | US | claimed |
| US-6680401-B1 | BORON COMPOUNDS SUCH AS 4-(METHOXYMETHYL)-1,3,2-DIOXABOROLANE, USED AS COUPLERS OR CHEMICAL INTERMEDIATES FOR DRUGS, PESTICIDES OR IN COMBINATORIAL CHEMISTRY | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2004-01-20 | — | — | US | claimed |
| EP-1127060-A4 | HYDROBORONATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2002-08-21 | — | — | EP | claimed |
| EP-1127060-A1 | HYDROBORONATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2001-08-29 | — | — | EP | claimed |
| WO-2000027853-A1 | HYDROBORONATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-05-18 | — | — | WO | claimed |
| US-20250340537-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING PENDRIN | ARBORMED CO LTD (KR) | 2025-11-06 | — | — | US | disclosed |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4642775-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING PENDRIN | Arbormed Co., Ltd. (KR) | 2025-11-05 | — | — | EP | disclosed |
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| CN-115572254-B | 2, 6-Diaryl pyridine HDAC/Tubulin dual-function inhibitor and preparation method and application thereof | 复旦大学 | 2025-04-01 | — | — | CN | disclosed |
| US-6680401-B1 | BORON COMPOUNDS SUCH AS 4-(METHOXYMETHYL)-1,3,2-DIOXABOROLANE, USED AS COUPLERS OR CHEMICAL INTERMEDIATES FOR DRUGS, PESTICIDES OR IN COMBINATORIAL CHEMISTRY | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2004-01-20 | — | — | US | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| EP-1127060-A4 | HYDROBORONATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2002-08-21 | — | — | EP | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
| EP-1127060-A1 | HYDROBORONATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000027853-A1 | HYDROBORONATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | CSF1R 1916/4885CA1 2508/4885CA2 1670/4885 |
| US-20250340537-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING PENDRIN | SLC26A4, PTH1R, PKD1 | CSF1R 3495/4885CA1 1649/4885CA2 392/4885 |
| US-20040133028-A1 | Hydroboronation process | ALKBH3, HPD, HVCN1 | CSF1R 3213/4885CA1 2357/4885CA2 1595/4885 |
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | CSF1R 485/4885CA1 2801/4885CA2 3081/4885 |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | CSF1R 1916/4885CA1 2508/4885CA2 1670/4885 |
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | HDAC1, HDAC11, HDAC5 | CSF1R 4356/4885CA1 740/4885CA2 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.